cilnidipine
Small moleculeexperimental
Clinical trial activity
8 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
2
Phase 4
2
Earliest trial started Jan 1, 2005 (NCT00325637)
Timeline
Indications
Approved for
Mechanism of action
- L-type calcium channelANTAGONIST
L-type calcium channel antagonist
N-type calcium channel alpha-1b/alpha2delta-1/beta-1b antagonist
Voltage-gated L-type calcium channel blocker
Also active against N-type calcium channels which may contribute to additional organ protective effects.
Chemistry & pharmacology
Loading structure…
SMILES
COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)C1c1cccc([N+](=O)[O-])c1- Mol. weight
- 492.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL452076 ↗
Also known as
- 2-methoxyethyl-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate
- cilnidipine
- cilnidipine
- cilnidipine
- cilnidipine
- cilnidipine
- cilnidipine
- cilnidipine
- cilnidipine, (-)-isomer
- cilnidipine, (+)-isomer
- cinaldipine
- cinalong
- clinidipine
- frc 8653
- frc-8653
- frc-8653
- frc-8653
- frc-8653
- frc-8653
- frc-8653
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02343250 | Phase 1 | Mar 1, 2015 | IlDong Pharmaceutical Co Ltd, Seoul National University |
| NCT02088008 | Phase 1 | May 1, 2014 | IlDong Pharmaceutical Co Ltd |
| NCT02145104 | Phase 3 | May 1, 2014 | IlDong Pharmaceutical Co Ltd, Seoul National University |
| NCT01838967 | Phase 1 | Apr 1, 2013 | IlDong Pharmaceutical Co Ltd, Seoul National University |
| NCT00890279 | Phase 2 | Jul 1, 2009 | Government of Japan, Teikyo University |
| NCT00541853 | Phase 4 | Dec 1, 2007 | Government of Japan, Kyorin University |
| NCT00325936 | Phase 4 | Jul 1, 2005 | Boryung Pharmaceutical Company, Catholic University of Korea, Chonnam National University, Inje University, Kyungpook University, Seoul National University, Sungkyunkwan University, Yonsei University |
| NCT00325637 | Phase 3 | Jan 1, 2005 | Boryung Pharmaceutical Company, Eulji University, Inha University, Inje University, Seoul National University, University of Ulsan |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Seoul National University | Academic/Hospital | 5 | 0 | 3 | 2005 |
| IlDong Pharmaceutical Co Ltd | For profit | 4 | 4 | 2 | 2013 |
| Boryung Pharmaceutical Company | For profit | 2 | 2 | 2 | 2005 |
| Government of Japan | Government | 2 | 1 | 2 | 2007 |
| Inje University | Academic/Hospital | 2 | 0 | 2 | 2005 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Chonnam National University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Eulji University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Inha University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Kyorin University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Kyungpook University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Teikyo University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2005 |
15 organizations
Page 1 / 1